Cargando…

Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy

The increasing frequency of infections caused by multidrug-resistant Klebsiella pneumoniae demands the development of unconventional therapies. Here, we isolated, characterized, and sequenced a Klebsiella phage PG14 that infects and lyses carbapenem-resistant K. pneumoniae G14. Phage PG14 showed mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulani, Mansura S., Kumkar, Shital N., Pardesi, Karishma R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769620/
https://www.ncbi.nlm.nih.gov/pubmed/36374021
http://dx.doi.org/10.1128/spectrum.01994-22
_version_ 1784854411030298624
author Mulani, Mansura S.
Kumkar, Shital N.
Pardesi, Karishma R.
author_facet Mulani, Mansura S.
Kumkar, Shital N.
Pardesi, Karishma R.
author_sort Mulani, Mansura S.
collection PubMed
description The increasing frequency of infections caused by multidrug-resistant Klebsiella pneumoniae demands the development of unconventional therapies. Here, we isolated, characterized, and sequenced a Klebsiella phage PG14 that infects and lyses carbapenem-resistant K. pneumoniae G14. Phage PG14 showed morphology similar to the phages belonging to the family Siphoviridae. The adsorption curve of phage PG14 showed more than 90% adsorption of phages on a host within 12 min. A latent period of 20 min and a burst size of 47 was observed in the one step growth curve. Phage PG14 is stable at a temperature below 30°C and in the pH range of 6 to 8. The PG14 genome showed no putative genes associated with virulence and antibiotic resistance. Additionally, it has shown lysis against 6 out of 13 isolates tested, suggesting the suitability of this phage for therapeutic applications. Phage PG14 showed more than a 7-log cycle reduction in K. pneumoniae planktonic cells after 24 h of treatment at a multiplicity of infection (MOI) of 10. The phage PG14 showed a significant inhibition and disruption of biofilm produced by K. pneumoniae G14. The promising results of this study nominate phage PG14 as a potential candidate for phage therapy. IMPORTANCE Klebsiella pneumoniae is one of the members of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) group of pathogens and is responsible for nosocomial infections. The global increase of carbapenem-resistant K. pneumoniae has developed a substantial clinical threat because of the dearth of therapeutic choices available. K. pneumoniae is one of the commonly found bacteria responsible for biofilm-related infections. Due to the inherent tolerance of biofilms to antibiotics, there is a growing need to develop alternative strategies to control biofilm-associated infections. This study characterized a novel bacteriophage PG14, which can inhibit and disrupt the K. pneumoniae biofilm. The genome of phage PG14 does not show any putative genes related to antimicrobial resistance or virulence, making it a potential candidate for phage therapy. This study displays the possibility of treating infections caused by multidrug-resistant (MDR) isolates of K. pneumoniae using phage PG14 alone or combined with other therapeutic agents.
format Online
Article
Text
id pubmed-9769620
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-97696202022-12-22 Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy Mulani, Mansura S. Kumkar, Shital N. Pardesi, Karishma R. Microbiol Spectr Research Article The increasing frequency of infections caused by multidrug-resistant Klebsiella pneumoniae demands the development of unconventional therapies. Here, we isolated, characterized, and sequenced a Klebsiella phage PG14 that infects and lyses carbapenem-resistant K. pneumoniae G14. Phage PG14 showed morphology similar to the phages belonging to the family Siphoviridae. The adsorption curve of phage PG14 showed more than 90% adsorption of phages on a host within 12 min. A latent period of 20 min and a burst size of 47 was observed in the one step growth curve. Phage PG14 is stable at a temperature below 30°C and in the pH range of 6 to 8. The PG14 genome showed no putative genes associated with virulence and antibiotic resistance. Additionally, it has shown lysis against 6 out of 13 isolates tested, suggesting the suitability of this phage for therapeutic applications. Phage PG14 showed more than a 7-log cycle reduction in K. pneumoniae planktonic cells after 24 h of treatment at a multiplicity of infection (MOI) of 10. The phage PG14 showed a significant inhibition and disruption of biofilm produced by K. pneumoniae G14. The promising results of this study nominate phage PG14 as a potential candidate for phage therapy. IMPORTANCE Klebsiella pneumoniae is one of the members of the ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) group of pathogens and is responsible for nosocomial infections. The global increase of carbapenem-resistant K. pneumoniae has developed a substantial clinical threat because of the dearth of therapeutic choices available. K. pneumoniae is one of the commonly found bacteria responsible for biofilm-related infections. Due to the inherent tolerance of biofilms to antibiotics, there is a growing need to develop alternative strategies to control biofilm-associated infections. This study characterized a novel bacteriophage PG14, which can inhibit and disrupt the K. pneumoniae biofilm. The genome of phage PG14 does not show any putative genes related to antimicrobial resistance or virulence, making it a potential candidate for phage therapy. This study displays the possibility of treating infections caused by multidrug-resistant (MDR) isolates of K. pneumoniae using phage PG14 alone or combined with other therapeutic agents. American Society for Microbiology 2022-11-14 /pmc/articles/PMC9769620/ /pubmed/36374021 http://dx.doi.org/10.1128/spectrum.01994-22 Text en Copyright © 2022 Mulani et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Mulani, Mansura S.
Kumkar, Shital N.
Pardesi, Karishma R.
Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title_full Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title_fullStr Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title_full_unstemmed Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title_short Characterization of Novel Klebsiella Phage PG14 and Its Antibiofilm Efficacy
title_sort characterization of novel klebsiella phage pg14 and its antibiofilm efficacy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769620/
https://www.ncbi.nlm.nih.gov/pubmed/36374021
http://dx.doi.org/10.1128/spectrum.01994-22
work_keys_str_mv AT mulanimansuras characterizationofnovelklebsiellaphagepg14anditsantibiofilmefficacy
AT kumkarshitaln characterizationofnovelklebsiellaphagepg14anditsantibiofilmefficacy
AT pardesikarishmar characterizationofnovelklebsiellaphagepg14anditsantibiofilmefficacy